Real-World study checks how well oral semaglutide controls diabetes
NCT ID NCT05443191
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 50 adults with type 2 diabetes who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers tracked changes in blood sugar (HbA1c) and body weight over about 8-10 months. Participants also filled out a questionnaire about how they took the medication. The goal was to see how well the drug works in everyday life, not in a controlled lab setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Rybelsus)
What this could lead to
If successful, this could confirm that oral semaglutide helps control blood sugar and weight in real-world settings, supporting its use for type 2 diabetes management.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to everyone. It does not test new effects or compare with other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aava Lääkärikeskus Kamppi
Helsinki, 00100, Finland
-
Master Centre for Finland
Helsinki, Finland, 00100, Finland
-
Master centre for France_Paris La défense cedex
Paris, La Défense, cedex, France